Share Prices & Company Research

Stockbroking

GlaxoSmithKline

Current Price 1218.60p Bid 1218.60p Ask 1218.80p Change 0.83%
Last Updated: 04/03/2021 08:40. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

UK-based GlaxoSmithKline is one of the world's leading pharmaceutical research companies. The company was created out of the merger between GlaxoWellcome and SmithKline Beecham in 2000.

Financial Highlights Year Ended 31/12/2020

Revenue
£34,099.00m
Operating Profit/Loss
£7,783.00m
Dividend yield (%)
5.90
Total dividend for year
n/ap
Dividend cover
1.45
P/E Ratio
11.60

Key Personnel

Ms Emma Walmsley
Chief Executive Officer
Mr Iain Mackay
Chief Financial Officer
Mr Hal Barron
Chief Scientific Officer
Dr Jesse Goodman
Independent Non-Executive Director
Dr Laurie Glimcher
Independent Non-Executive Director
Mr Urs Rohner
Independent Non-Executive Director
Ms Judy Lewent
Independent Non-Executive Director
Ms Lynn Elsenhans
Independent Non-Executive Director
Ms Vivienne Cox
Independent Non-Executive Director
Mr Jonathan Symonds
Non-Executive Chairman
Mr Charles Bancroft
Non-Executive Director
Mr Manvinder Singh Banga
Senior Independent Non-Executive Director

Stock Details

EPIC
GSKL
ISIN
GB0009252882
Shares in Issue
4,870.09m
Market cap
£59,346.91m

Analyst Views (7)

Strong Buy
 
0%
Buy
 
28.57%
Hold
 
28.57%
Sell
 
42.86%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect the views held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
1,218.60p
Bid Price
1,218.60p
Ask Price
1,218.80p
Volume
184,080
Change Today
10.00p
% Change Today
0.83%
Open
1,208.30p
Previous Close
1,208.60p
Intraday High
1,218.60p
Intraday Low
1,204.20p
52 Week High
1,728.60p
52 Week Low
1,192.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

News

GSK Covid-19 monoclonal treatment shows potential benefit for older patients 25/02/2021 19:21:15 GSK and Sanofi start phase 2 trial on refined Covid-19 vaccine 22/02/2021 11:05:37 GSK, Vir to collaborate on new therapeutics for influenza 17/02/2021 12:02:13 Sanofi Covid-19 vaccines may be ready by end of 2021 15/02/2021 12:17:29 Deutsche Bank cuts GlaxoSmithKline to 'sell', says valuation alone is not enough 04/02/2021 15:54:06 GlaxoSmithKline forecasts decline in 2021 earnings, shares slump 03/02/2021 12:11:59 GSK, Curevac in venture to develop vaccine for Covid-19 variants 03/02/2021 07:01:40 Hikma mulls acquisition of GlaxoSmithKline assets in Egypt and Tunisia 26/01/2021 08:42:14 GlaxoSmithKline's ViiV gets FDA approval for 'Cabenuva' 22/01/2021 07:48:59 Credit Suisse downgrades Glaxo, highlights near-term challenges 20/01/2021 10:11:42 Glaxo not seeking re-hearing in Ellipta litigation, says Vectura 29/12/2020 10:04:05 GlaxoSmithKline's ViiV gets EU authorisation for complete HIV treatment 21/12/2020 08:08:52 GSK and Sanofi delay Covid-19 vaccine 11/12/2020 07:02:05 Court denies GSK appeal in Vectura intellectual property dispute 20/11/2020 08:34:00 GlaxoSmithKline upbeat on HIV treatment test results in women 09/11/2020 08:12:41 GSK sees FY EPS at lower end of guidance as Covid hits vaccines business 28/10/2020 12:03:00 Glaxo, Sanofi pledge 200m Covid doses to global facility 28/10/2020 07:15:48 Wednesday preview: US foreign trade, GlaxoSmithKline in the spotlight 27/10/2020 16:43:39 EU agrees to purchase Sanofi/GSK Covid-19 vaccine 18/09/2020 11:01:39 GSK, Sanofi start trials of Covid-19 vaccine 03/09/2020 07:03:39 GSK receives FDA approval for BLENREP 06/08/2020 08:02:25 Sanofi under investigation on charges including manslaughter 03/08/2020 11:26:15 GSK and Sanofi in talks to supply 300m vaccine doses to EU 03/08/2020 07:43:48 Washington to support GSK and Sanofi Covid-19 vaccine with $2.1bn 31/07/2020 12:35:06 GlaxoSmithKline stands by full-year EPS guidance but with a caveat 29/07/2020 12:30:34

Income Statement

Year End Date
31 Dec 2020
31 Dec 2019
 
£ (M)
£ (M)
Continuing Operations
Revenue
34,099.00
33,754.00
Operating Profit/Loss
7,783.00
6,961.00
Net Interest
-848.00
-814.00
Pre-Tax Profit
6,968.00
6,221.00
Profit After Tax from continuing operations
6,388.00
5,268.00
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
6,388.00
5,268.00
Attributable to:
Equity Holders of Parent Company
5,749.00
4,645.00
Minority Interests
639.00
623.00
Total Dividend Paid
n/ap
n/ap
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2020
31 Dec 2019
Basic
115.50p
93.90p
Diluted
114.10p
92.60p
Adjusted
115.90p
123.90p
Dividend per Share
n/ap
n/ap

Assets

Year End Date
31 Dec 2020
31 Dec 2019
 
£ (M)
£ (M)
Non-Current Assets
Property, Plant & Equipment
11,006.00
10,348.00
Intangible Assets
40,421.00
41,517.00
Investment Properties
n/a
n/a
Investments
3,424.00
2,151.00
Other Financial Assets
5.00
103.00
Other Non-Current Assets
5,328.00
6,082.00
Current Assets
Inventories
5,996.00
5,947.00
Trade & Other Receivables
6,952.00
7,464.00
Cash at Bank & In Hand
6,292.00
4,707.00
Current Asset Investments
n/a
n/a
Other Current Assets
1,007.00
1,373.00
Other Assets
n/a
n/a
Total Assets
80,431.00
79,692.00

Liabilities

Year End Date
31 Dec 2020
31 Dec 2019
 
£ (M)
£ (M)
Current Liabilities
Borrowings
3,725.00
6,918.00
Other Current Liabilities
18,423.00
17,132.00
Total Current Liabilities
22,148.00
24,050.00
Non-Current Liabilities
Borrowings
23,425.00
23,590.00
Provisions
4,307.00
4,480.00
Other Non-Current Liabilities
9,743.00
9,215.00
Total Non-Current Liabilities
37,475.00
37,285.00
Other Liabilities
n/a
n/a
Total Liabilities
59,623.00
61,335.00

Net Assets

Year End Date
31 Dec 2020
31 Dec 2019
 
£ (M)
£ (M)
Net Assets
20,808.00
18,357.00

Capital & Reserves

Year End Date
31 Dec 2020
31 Dec 2019
 
£ (M)
£ (M)
Share Capital
1,346.00
1,346.00
Share Premium Account
3,281.00
3,174.00
Other Reserves
3,205.00
2,355.00
Retained Earnings
6,755.00
5,109.00
Shareholders Funds
14,587.00
11,984.00
Minority Interests/Other Equity
6,221.00
6,373.00
Total Equity
20,808.00
18,357.00

Dividend History

Type
Ex-Dividend Date
Payment Date
Payment
Q4
18 Feb 2021
08 Apr 2021
23.00p
Q3
12 Nov 2020
14 Jan 2021
19.00p
Q2
13 Aug 2020
08 Oct 2020
19.00p
Q1
14 May 2020
09 Jul 2020
19.00p
Q4
20 Feb 2020
09 Apr 2020
23.00p
Q3
14 Nov 2019
09 Jan 2020
19.00p
Q2
08 Aug 2019
10 Oct 2019
19.00p
Q1
16 May 2019
11 Jul 2019
19.00p
Q4
21 Feb 2019
11 Apr 2019
23.00p
Q3
15 Nov 2018
10 Jan 2019
19.00p
Q2
09 Aug 2018
11 Oct 2018
19.00p
Q1
10 May 2018
12 Jul 2018
19.00p
Q4
22 Feb 2018
12 Apr 2018
23.00p
Q3
09 Nov 2017
11 Jan 2018
19.00p
Q2
10 Aug 2017
12 Oct 2017
19.00p
Q1
11 May 2017
13 Jul 2017
19.00p
Q4
23 Feb 2017
13 Apr 2017
23.00p
Q3
03 Nov 2016
12 Jan 2017
19.00p
Q2
11 Aug 2016
13 Oct 2016
19.00p
Q1
12 May 2016
14 Jul 2016
19.00p
Special
18 Feb 2016
14 Apr 2016
20.00p
Q4
18 Feb 2016
14 Apr 2016
23.00p
Q4
18 Feb 2016
14 Apr 2016
23.00p
Q3
12 Nov 2015
14 Jan 2016
19.00p
Q2
13 Aug 2015
01 Oct 2015
19.00p
Q1
14 May 2015
09 Jul 2015
19.00p

Dividend Metrics

Year End Date
31 Dec 2020
31 Dec 2019
Dividend growth
n/a%
n/a%
Dividend yield
5.90%
4.50%
Dividend cover
1.45
1.55


Cboe Global Markets® is a registered trade mark of Cboe Global Markets, Inc., a company incorporated in the United States of America with registered address at 400 South LaSalle Street, Chicago, IL 60605, USA. Cboe shall own any and all rights including without limitation Intellectual Property rights and any and all goodwill arising directly or indirectly out of the Recipient’s use of the “Cboe Global Markets®”, “Cboe®” and “Bats®”” trademarks. Neither Cboe nor its licensors accept any liability for any errors or omissions in the Cboe Europe Indices or underlying data. No further distribution of Cboe Europe data is permitted without Cboe’s express written consent.

The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 1st March 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.